The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.

The initiative will enable young people aged 12 to 18 to collaborate with campus researchers in the design, development and communication of scientific projects, placing patients and families at the centre of the research process.

The donation will support a research line focused on understanding the progression of this inflammatory liver disease and improving treatment personalisation.

The REACH5 study confirms that the efficacy and safety results observed in previous studies are maintained after three years of follow-up.

In-depth knowledge of tumours helps identify specific alterations and enables the provision of targeted therapies for each patient.

The charitable initiative created in honor of Pol is supporting a research project aimed at identifying therapeutic targets to treat a rare type of leukemia.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

The donation will support a project investigating new therapeutic approaches in pediatric brain tumors

The €15,000 donation will boost research into this very rare type of childhood cancer.

The association has donated €15,088 to the Childhood Cancer and Blood Disorders group at VHIR to improve the treatment of rhabdomyosarcoma.

The Iris Association has made a €14,499 donation to the Childhood Cancer and Hematological Diseases Group at the Vall d’Hebron Research Institute (VHIR).

The funds raised will contribute to ensuring the continuity of the pediatric brain tumor research line developed by the Vall d’Hebron research teams.

During the annual meeting, representatives from the different centers participating in the project shared the progress made across the various areas of work.

The collaboration between the Vall d’Hebron Research Institute (VHIR) and the Association for Information and Research on Familial Hypomagnesemia (Hipofam) celebrates ten years.

The aim of the project is to establish kidney organoids derived from patients with familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, which will be essential tools for studying the disease and testing new treatments.

2025 has been an active year with the participation of RADeep members at the Data Access Committee at Vall d’Hebron and the presentation of abstracts at the 67th ASH Annual Meeting and Exposition.

L’aportació permet avançar en estudis de referència internacional i continuar millorant l’atenció dels infants trasplantats de fetge.

Since 2019, Pulseras Candela has been collaborating with the Childhood Cancer and Hematological Diseases group at VHIR on the project “New Therapeutic Approaches for the Treatment of Pediatric Ependymoma.”

The donation will boost several lines of research to advance liquid biopsy in pediatric sarcomas and brain tumors.

The work, awarded €25,000, studies respiratory syncytial virus (RSV) variants in children following the introduction of nirsevimab.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

Genetic susceptibility to developing ADHD shows the strongest association with mental health problems during childhood and adolescence, compared to genetic risk for other psychiatric conditions.